- The European Blood Alliance (EBA) joined hands with the European Commission, consisting of DG CNECT, DG DIGIT and DG SANTE in May’2020. The partnership aims at building and managing an EU-wide, open-access platform that gathers data on the COVID-19 convalescent plasma therapy
Frequently Asked Questions
The market is segmented based on Segmentation, By Type (Hyperimmune Globulin, Albumin, Factor VIII, Factor IX, Immunoglobulin and Others), Mode of Delivery (Infusion Solutions, Gels, Sprays, Biomedical Sealants), Therapeutic Indication (Immunology, Oncology, Pulmonology, Rheumatology, Transplantation, Neurology, Hematology and Other), Application (Hypogammaglobulinemia, Immunodeficiency Diseases, Hemophilia, Von Willebrand's Disease (vWD) and Others), End User (Hospitals, Clinics and Other) - Industry Trends and Forecast to 2031.
.
The Global Blood Plasma Market size was valued at USD 31.61 USD Billion in 2023.
The Global Blood Plasma Market is projected to grow at a CAGR of 10.6% during the forecast period of 2024 to 2031.
The major players operating in the market include Allergan, AbbVie , GALDERMA, Evolus , Revance, HUGEL , Ipsen Pharma, USWM LLC, Sun Pharmaceutical Industries , Pfizer , GlaxoSmithKline plc, Merz Pharma, Medytox, Smith+Nephew, Sanofi, Novartis AG, Teva Pharmaceutical Industries , LGM Pharma, Lannett, NorthStar Rx LLC, Par Pharmaceutical.
The market report covers data from the U.S., Canada and Mexico in North America, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.
